Drug Profile
Testosterone topical - AbbVie/Besins/Viatris
Alternative Names: 1% Testosterone gel (AndroGel) - AbbVie; 1.62% Testosterone gel - Solvay; AndroGel; AndroGel PD; Testogel; Testosterone topical - AbbottLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Besins International; Unimed Pharmaceuticals
- Developer AbbVie; Besins Healthcare; Solvay
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Growth stimulants; Testosterone congener stimulants; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypogonadism
- Discontinued Growth disorders
Most Recent Events
- 23 Oct 2023 Solvay withdraws a phase-II trial in Hypogonadism and Pain in USA prior to enrolment (NCT00398034)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 07 Aug 2018 Solvay Pharmaceuticals completes a phase I trial in Hypogonadism in USA (Topical) (NCT00425568)